Use your browser's back button to choose another title or click here for a New Search.


How to Get the Poster

 Open poster (pdf)

 

Bookmark and Share

 

 

 

 

HIV Testing History of Drug Treatment Participants in the US.

Poster presented at the International AIDS Society (IAS) Conference, Washington, DC, July 22-27, 2012.

Raul N. Mandler, MD (Center for the Clinical Trials Network (CCTN), NIDA), Antoine B. Douaihy, MD (Addiction Medicine Services, WPIC, AT Node), Daniel J. Feaster, PhD (University of Miami Miller School of Medicine, FNA Node), P. Todd Korthuis, MD, MPH (Oregon Health & Science University, WS Node), Susan Tross, PhD (NY State Psychiatric Institute, GNY Node), Moupali Das, MD, MPH (SF Department of Public Health, WS Node), Gilbert Saint-Jean, MD, MPH, PhD, Rosa Verdeja, Lisa R. Metsch, PhD (last three from University of Miami Miller School of Medicine, FNA Node), Grant N. Colfax, MD (SF Department of Public Health, WS Node).

In the USA, HIV testing is recommended for everyone between the ages of 13 and 64, regardless of risk. Many individuals, however, are never tested for HIV. Substance treatment services may represent important opportunities to increase HIV testing. This poster reports on an ancillary investigation of data from protocol CTN-0032, "HIV Rapid Testing and Counseling," intended to analyze participant responses on socio-demographic characteristics, HIV testing history, type of treatment facility, and other factors.

A total of 896 of the 1281 participants in the study reported having been tested at some point in the past. Of the 895 participants who responded, 192 reported that they had not received the results of their test. The most frequent reasons for not receiving results were believing the clinic would contact positive patients proactively (35%), jail-related reasons (got tested in jail and then released, or vice versa, 14.3%), or "forgot to get the result" (7.5%). Fear or lack of interest in the result, or being "too busy" to get the result, was reported by only 7 patients each. Both participants from residential treatment programs and from outpatient treatment programs were less likely to have been HIV tested than were participants from within opioid treatment sites. Participants in residential treatment were also significantly less likely to have been HIV tested than were participants from outpatient treatment. Neither level of care nor site significantly predicted the probability of receiving the results of the last HIV for participants.

Conclusions: Substance use treatment is an appropriate venue for increasing HIV testing. The poster reports on a variety of suggestions for targeting efforts, focused on both venue effects (type of treatment program) and participant characteristics such as race; gender; type of drug used; condom self-efficacy; and education, marital, and incarceration status. (Poster, PowerPoint slides, English, 2012)

Keywords: Condom use | CTN platform/ancillary study | HIV/AIDS | Sexual risk behavior | Sexually transmitted diseases | International AIDS Society (IAS) conference, 2012

Document No: 900

Submitted by Raul Mandler, MD, 8/21/2012.

 

AUTHORS SEARCH LINK
Colfax, Grant N.
Das, Moupali mail
Douaihy, Antoine B. mail
Feaster, Daniel J. search mail
Korthuis, P. Todd search mail
Mandler, Raul N. search mail
Metsch, Lisa R. search mail
Saint-Jean, Gilbert search
Tross, Susan search mail
Verdeja, Rosa search
PROTOCOLS
NIDA-CTN-0032 www
PARTICIPATING NODES
Florida Node Alliance (Lead) www
Appalachian Tri-State www
Mid-Atlantic www
New England Consortium www
Southern Consortium www
Southwest www
Western States www


dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 8/2012 -- http://ctndisseminationlibrary.org/display/900.htm
info@ctndisseminationlibrary.org
dark blue line